APA (7th ed.) Citation

F, L., N, G., BS, K., H, N., B, B., PD, P., . . . SM, T. (2026). A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 489. https://doi.org/10.1158/1078-0432.CCR-25-0571

Chicago Style (17th ed.) Citation

F, Lynce, et al. "A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 32, no. 3 (2026): 489. https://doi.org/10.1158/1078-0432.CCR-25-0571.

MLA (9th ed.) Citation

F, Lynce, et al. "A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 32, no. 3, 2026, p. 489, https://doi.org/10.1158/1078-0432.CCR-25-0571.